[go: up one dir, main page]

MA33767B1 - Nouvelle utilisation anticancéreuse du cabazitaxel - Google Patents

Nouvelle utilisation anticancéreuse du cabazitaxel

Info

Publication number
MA33767B1
MA33767B1 MA34898A MA34898A MA33767B1 MA 33767 B1 MA33767 B1 MA 33767B1 MA 34898 A MA34898 A MA 34898A MA 34898 A MA34898 A MA 34898A MA 33767 B1 MA33767 B1 MA 33767B1
Authority
MA
Morocco
Prior art keywords
cancer
capsules
new use
treatment
prostate
Prior art date
Application number
MA34898A
Other languages
Arabic (ar)
English (en)
Inventor
Sunil Gupta
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA33767B1 publication Critical patent/MA33767B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

L'invention concerne un composé de formule (I) pouvant se présenter sous la forme d'une base ou d'un hydrate ou d'un solvate, en combinaison avec prednisone ou prednisolone, pour être utilisé comme médicament dans le traitement du cancer de la prostate, en particulier le cancer métastasique de la prostate, spécialement pour des patients qui ne sont pas soumis à un traitement à base de taxane.
MA34898A 2009-10-29 2012-05-25 Nouvelle utilisation anticancéreuse du cabazitaxel MA33767B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US29390310P 2010-01-11 2010-01-11
US35583410P 2010-06-17 2010-06-17
US35588810P 2010-06-17 2010-06-17
US36992910P 2010-08-02 2010-08-02
US38393310P 2010-09-17 2010-09-17
US38996910P 2010-10-05 2010-10-05
PCT/IB2010/054866 WO2011051894A1 (fr) 2009-10-29 2010-10-27 Nouvelle utilisation antitumorale du cabazitaxel

Publications (1)

Publication Number Publication Date
MA33767B1 true MA33767B1 (fr) 2012-11-01

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34898A MA33767B1 (fr) 2009-10-29 2012-05-25 Nouvelle utilisation anticancéreuse du cabazitaxel

Country Status (31)

Country Link
US (8) US8927592B2 (fr)
EP (1) EP2493466B1 (fr)
JP (2) JP5566466B2 (fr)
KR (1) KR101712231B1 (fr)
CN (1) CN102770131A (fr)
AR (1) AR078824A1 (fr)
AU (4) AU2010310986A1 (fr)
BR (1) BR112012011457A2 (fr)
CA (1) CA2779009A1 (fr)
CR (1) CR20120204A (fr)
DK (1) DK2493466T3 (fr)
EA (1) EA024186B1 (fr)
EC (1) ECSP12011836A (fr)
ES (1) ES2862340T3 (fr)
GT (1) GT201200123A (fr)
IL (3) IL219443A0 (fr)
MA (1) MA33767B1 (fr)
MX (1) MX336339B (fr)
MY (1) MY164086A (fr)
NI (1) NI201200071A (fr)
PE (1) PE20121429A1 (fr)
PH (1) PH12012500848A1 (fr)
PL (1) PL2493466T3 (fr)
PT (1) PT2493466T (fr)
SG (1) SG10201810928SA (fr)
SV (1) SV2012004192A (fr)
TN (1) TN2012000188A1 (fr)
TW (2) TWI654975B (fr)
UY (1) UY32987A (fr)
WO (1) WO2011051894A1 (fr)
ZA (1) ZA201203123B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
PL2493466T3 (pl) * 2009-10-29 2021-11-15 Sanofi Mature Ip Nowe przeciwguzowe zastosowanie kabazytakselu
JP2014514306A (ja) * 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
EP2791122B1 (fr) 2011-12-13 2019-01-23 Aventis Pharma S.A. Forme cristalline du cabazitaxel et son procédé de préparation
US9403785B2 (en) * 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
EP2880021A4 (fr) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd Cabazitaxel amorphe
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (fr) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
PT3258931T (pt) 2015-02-17 2020-09-23 Univ Erasmus Med Ct Rotterdam Utilização do cabazitaxel no tratamento do cancro da próstata
EP3093014A1 (fr) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel et son utilisation pour le traitement du cancer
EP3509569A1 (fr) 2016-09-07 2019-07-17 Cadila Healthcare Limited Compositions stériles injectables comprenant médicament micellaires
US20170281651A1 (en) * 2017-03-01 2017-10-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors
WO2018187786A1 (fr) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Cellules unipotentes progénitrices de neutrophiles, procédés de préparation et utilisations associées
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
TR200100575T2 (tr) 1998-08-20 2001-07-23 Aventis Pharma S.A. Taksoid türevlerinin yeni kullanım alanları
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
DE50301051D1 (de) 2003-07-02 2005-09-29 Scheuten Glasgroep Venlo Verfahren zur Herstellung einer Brandschutzverglasung
EP1498120A1 (fr) 2003-07-18 2005-01-19 Aventis Pharma S.A. Formulation semi-solide pour l'administration orale du taxol
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CA2589918A1 (fr) 2004-12-08 2006-06-15 Dorre Grueneberg Methode permettant de mesurer la resistance ou la sensibilite au docetaxel comprenant la detection de tacc3
EP1700596A1 (fr) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Utilisation de composés stabilisant les microtubules pour le traitement des lesions axonales du SNC
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (fr) 2008-10-02 2010-04-21 Institut Gustave Roussy Procédés de prédiction ou de suivi du fait qu'un patient atteint d'un cancer répond à une traitement par une molécule de la famille des taxoïdes
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
BRPI1014854A2 (pt) 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PL2493466T3 (pl) 2009-10-29 2021-11-15 Sanofi Mature Ip Nowe przeciwguzowe zastosowanie kabazytakselu
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
BR112012012210B8 (pt) 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
WO2011124669A1 (fr) 2010-04-08 2011-10-13 Institut Gustave Roussy Procédés de prédiction ou de surveillance pour savoir si un patient atteint d'un cancer répond à un traitement par une molécule de la famille des taxoïdes
WO2011130317A2 (fr) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Agents thérapeutiques ayant une toxicité réduite
JP5975983B2 (ja) 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法
EP3093014A1 (fr) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel et son utilisation pour le traitement du cancer
EP3808345A1 (fr) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène

Also Published As

Publication number Publication date
CA2779009A1 (fr) 2011-05-05
US20120301425A1 (en) 2012-11-29
ECSP12011836A (es) 2012-07-31
JP5566466B2 (ja) 2014-08-06
PH12012500848A1 (en) 2016-02-08
EA201270606A1 (ru) 2013-01-30
US20200155497A1 (en) 2020-05-21
US8927592B2 (en) 2015-01-06
IL267583A (en) 2019-08-29
EP2493466B1 (fr) 2021-03-10
US10716777B2 (en) 2020-07-21
TW201611831A (en) 2016-04-01
DK2493466T3 (da) 2021-04-26
MX336339B (es) 2016-01-14
US20150118182A1 (en) 2015-04-30
US20150104411A1 (en) 2015-04-16
US20180125810A1 (en) 2018-05-10
GT201200123A (es) 2013-11-07
AU2019203514A1 (en) 2019-06-06
US12453712B2 (en) 2025-10-28
TWI654975B (zh) 2019-04-01
JP2013509394A (ja) 2013-03-14
AU2017232227A1 (en) 2017-10-12
TWI533866B (zh) 2016-05-21
TW201127374A (en) 2011-08-16
AU2010310986A1 (en) 2012-06-14
SG10201810928SA (en) 2019-01-30
UY32987A (es) 2011-05-31
WO2011051894A1 (fr) 2011-05-05
AU2016200598A1 (en) 2016-02-25
PL2493466T3 (pl) 2021-11-15
AU2017232227B2 (en) 2019-06-06
MX2012005030A (es) 2012-12-05
PE20121429A1 (es) 2012-11-06
JP6182510B2 (ja) 2017-08-16
ES2862340T3 (es) 2021-10-07
US20190151278A1 (en) 2019-05-23
ZA201203123B (en) 2013-06-26
EA024186B1 (ru) 2016-08-31
KR101712231B1 (ko) 2017-03-03
IL250254A0 (en) 2017-03-30
AR078824A1 (es) 2011-12-07
IL219443A0 (en) 2012-06-28
EP2493466A1 (fr) 2012-09-05
US20240139146A1 (en) 2024-05-02
PT2493466T (pt) 2021-03-29
KR20120093986A (ko) 2012-08-23
US10583110B2 (en) 2020-03-10
NI201200071A (es) 2012-08-20
TN2012000188A1 (en) 2013-12-12
US20210169843A1 (en) 2021-06-10
MY164086A (en) 2017-11-30
CN102770131A (zh) 2012-11-07
SV2012004192A (es) 2012-08-23
CR20120204A (es) 2012-07-04
BR112012011457A2 (pt) 2016-05-03
JP2014196323A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
MA33767B1 (fr) Nouvelle utilisation anticancéreuse du cabazitaxel
EP2470250A4 (fr) Placement optimisé d'une canule pour administration d'agents thérapeutiques au cerveau
EP2620432A3 (fr) Composés de diarylhydantoïne
EP3066923A3 (fr) Méthode de traitement de néphropathie chronique
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA40254B1 (fr) Polymorphes du selinexor
MX2014012695A (es) Derivados de isoindolona.
EP2331520A4 (fr) Dérivés de rosamine comme agents pour le traitement d'un cancer
WO2007149798A3 (fr) Biomarqueurs pour la progression de la maladie d'alzheimer
MA29600B1 (fr) Utilisation de sanglifehrine dans le virus de l'hepatite c
JP2015502926A5 (fr)
MX2011008195A (es) Derivados de indol como agentes anticancer.
EP2296654A4 (fr) Dérivés de 8-hydroxyquinoline pour le traitement d'hémopathies malignes
MA32506B1 (fr) Nouveaux composes
MA34806B1 (fr) Compositions pharmaceutiques
FR2933972B1 (fr) Procede de preparation d'une piece en carbure de silicium ne necessitant pas l'usage d'ajouts de frittage
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
TN2011000551A1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
TN2011000542A1 (fr) Combinaison antitumorale comprenant le cabazitaxel et la capecitabine
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
EP2427438A4 (fr) Pyrimidine-2,4,6-triones destinée à être utilisée pour le traitement d'une sclérose latérale amyotrophe
JP2014532063A5 (fr)
MA38356A1 (fr) Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques
MA37438A1 (fr) Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora
TN2011000678A1 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones